Spacelabs Healthcare links Rothman Index to DEPTH Health as hospitals chase faster, safer bed movement
Spacelabs Healthcare and DEPTH Health are pairing Rothman Index analytics with patient flow tools. Read what this could change for hospitals.
How ATL Medical’s PREVOYANCE imaging system could speed arthroscopy device development with OMNIVISION’s OH0131 processor
ATL Medical and OMNIVISION have expanded arthroscopy imaging integration. Read what this means for OEM speed, quality, and device development.
Eli Lilly and Company’s Foundayo approval could widen the obesity market faster than rivals expected
Eli Lilly and Company’s Foundayo approval could reshape obesity treatment. Read what the oral GLP-1 launch changes for clinicians, payers, and rivals.
Can Peri turn perimenopause tracking into a credible new women’s health device category?
Peri has launched a perimenopause wearable, but can symptom tracking become clinical-grade insight? Read the deeper industry analysis now.
Why the Ro and Eli Lilly KwikPen move matters for obesity drug access, adherence, and pricing
Ro launches Eli Lilly’s Zepbound KwikPen nationwide. Read what this means for GLP-1 access, pricing, adherence, and obesity care models.
Why the Syra Health and Nora Mental Health deal matters for telebehavioral care in Indiana
Syra Health and Nora Mental Health are linking AI triage with teletherapy in Indiana. Read why this could reshape digital mental health access.
Cipla’s nintedanib approval opens a high-stakes test in the U.S. idiopathic pulmonary fibrosis market
Cipla’s nintedanib approval opens a new chapter in U.S. idiopathic pulmonary fibrosis care. Read what it changes for pricing, access, and competition.
Why SV Health Investors’ EpiVax acquisition signals a bigger private equity push into immunogenicity services
SV Health Investors acquires EpiVax. Read why immunogenicity risk assessment is becoming a more strategic pharma services market.
Vedanta Biosciences keeps VE303 Phase 3 trial on track as interim review clears futility bar
Vedanta Biosciences kept VE303 Phase 3 on track after interim review. Read what this means for recurrent C. difficile treatment and microbiome drug development.
What Innate Pharma’s Kempen conference participation reveals about its 2026 biotech strategy
Innate Pharma heads to Kempen as investors assess its oncology pipeline, partnering outlook, and next catalysts. Read the full analysis.